Skip to content
  • ENGLISHENGLISH
  • 繁體中文繁體中文
回首頁回首頁回首頁
  • About Alar
    • Company Profile
    • Leadership Team
    • History&Milestones
  • Products
    • Products Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Event
    • Knowledge
  • Investors
    • Shareholder Services
    • Financials
    • Corporate Governance
  • Contact Us
MENU Close

2020/07/22 ALA -1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI)

2020/07/22 ALA -1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI)

  • Post author:alarpharm
  • Post published:13 . 8 . 2020
  • Post category:Media releases

You Might Also Like

2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

14 . 1 . 2022

2021/08/25 ALA-1000 Receive notice of patent allowance from South Africa-Companies and Intellectual Property Commission Department of Trade and Industry (CIPC), Application No. 2019/00890.

3 . 9 . 2021

2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients

10 . 3 . 2021

2022/05/12 ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI , Application No. 000487-2019/DIN.

13 . 5 . 2022

2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046

8 . 6 . 2021
  • News
  • Event
  • Knowledge
回首頁

ABOUT

  • Company Profile
  • Leadership Team
  • History&Milestones
  • Company Profile
  • Leadership Team
  • History&Milestones

PRODUCTS

  • Products Pipeline
  • Contract Manufacturing
  • Products Pipeline
  • Contract Manufacturing

media

  • News
  • Event
  • Knowledge
  • News
  • Event
  • Knowledge

investors

  • Shareholder Services
  • Financials
  • Corporate Governance
  • Shareholder Services
  • Financials
  • Corporate Governance

CONTACT us

  • Contact Us
  • Contact Us
  • Contact Us
  • Privacy Policy
Copyright © - 2022 Alar Pharmaceuticals Inc . All right reserved.
Close
  • About Alar
    • Company Profile
    • Leadership Team
    • History&Milestones
  • Products
    • Products Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Event
    • Knowledge
  • Investors
    • Shareholder
    • Financials
    • Corporate Governance
  • Contact Us
    • Contact Us
×

Cart